120 related articles for article (PubMed ID: 1790049)
1. Reflotron performance in a community screening program: results of the Massachusetts Model Systems for Blood Cholesterol Screening Project.
Havas S; Bishop R; Koumjian L; Reisman J; Wozenski S
Am J Prev Med; 1991; 7(6):397-405. PubMed ID: 1790049
[TBL] [Abstract][Full Text] [Related]
2. Precision of a dry-chemistry method of lipid screening.
Bowden RG; Kingery PM; Long L
Public Health; 2006 Jun; 120(6):572-6. PubMed ID: 16730036
[TBL] [Abstract][Full Text] [Related]
3. Performance of the Reflotron in Massachusetts' Model System for Blood Cholesterol Screening Program.
Havas S; Bishop R; Koumjian L; Reisman J; Wozenski S
Am J Public Health; 1992 Mar; 82(3):458-61. PubMed ID: 1536371
[TBL] [Abstract][Full Text] [Related]
4. [Precision and accuracy of blood lipid analyses by a portable device (Cholestech-LDX)].
Issa JS; Strunz C; Giannini SD; Forti N; Diament J
Arq Bras Cardiol; 1996 Jun; 66(6):339-42. PubMed ID: 9035449
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of within-day precision of serum cholesterol measured by a portable analyzer.
Kaminsky LA; Whaley MH
Med Sci Sports Exerc; 1992 Jan; 24(1):134-8. PubMed ID: 1548987
[TBL] [Abstract][Full Text] [Related]
6. How accurately does the Reflotron dry-chemistry system measure plasma total cholesterol levels when used a community-screening device.
Phillips S; Wyndham L; Shaw J; Walker SF
Med J Aust; 1988 Aug; 149(3):122-5. PubMed ID: 3398798
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two point-of-care lipid analyzers for use in global cardiovascular risk assessments.
Dale RA; Jensen LH; Krantz MJ
Ann Pharmacother; 2008 May; 42(5):633-9. PubMed ID: 18413684
[TBL] [Abstract][Full Text] [Related]
8. Analytic and clinical performance of two compact cholesterol-testing devices.
Volles DF; McKenney JM; Miller WG; Ruffen D; Zhang D
Pharmacotherapy; 1998; 18(1):184-92. PubMed ID: 9469692
[TBL] [Abstract][Full Text] [Related]
9. The validity of the Reflotron as a screening tool for blood cholesterol.
Al-Humaidi MA; Abolfotouh MA; Sulaiman SA; Al-Kadoumi OF; Khattab MS; Al-Salmi HH; Al-Amari O; Saydain G; Al-Knawy B
J Egypt Public Health Assoc; 1997; 72(1-2):167-87. PubMed ID: 17265630
[TBL] [Abstract][Full Text] [Related]
10. [Measurement of cholesterol in capillary blood using the Reflotron system. Results from approximately 1,000 comparisons with reference measurements of cholesterol in venous serum].
Gerdes LU; Bak AM; Faergeman O
Ugeskr Laeger; 1990 Jun; 152(24):1739-43. PubMed ID: 2360292
[TBL] [Abstract][Full Text] [Related]
11. Interinstitutional comparison of bedside blood glucose monitoring program characteristics, accuracy performance, and quality control documentation: a College of American Pathologists Q-Probes study of bedside blood glucose monitoring performed in 226 small hospitals.
Novis DA; Jones BA
Arch Pathol Lab Med; 1998 Jun; 122(6):495-502. PubMed ID: 9625416
[TBL] [Abstract][Full Text] [Related]
12. Cholesterol screening: comparative evaluation of on-site and laboratory-based measurements.
Bachorik PS; Rock R; Cloey T; Treciak E; Becker D; Sigmund W
Clin Chem; 1990 Feb; 36(2):255-60. PubMed ID: 2302770
[TBL] [Abstract][Full Text] [Related]
13. The Centers for Disease Control-National Heart, Lung and Blood Institute Lipid Standardization Program. An approach to accurate and precise lipid measurements.
Myers GL; Cooper GR; Winn CL; Smith SJ
Clin Lab Med; 1989 Mar; 9(1):105-35. PubMed ID: 2538292
[TBL] [Abstract][Full Text] [Related]
14. Does cholesterol screening result in negative labeling effects? Results of the Massachusetts Model Systems for Blood Cholesterol Screening Project.
Havas S; Reisman J; Hsu L; Koumjian L
Arch Intern Med; 1991 Jan; 151(1):113-9. PubMed ID: 1789817
[TBL] [Abstract][Full Text] [Related]
15. Quality of lipid and lipoprotein measurements in community laboratories.
Watson JE; Evans RW; Germanowski J; Caggiula AW; Olson MB; Hauth BA
Arch Pathol Lab Med; 1997 Feb; 121(2):105-9. PubMed ID: 9126034
[TBL] [Abstract][Full Text] [Related]
16. A clinician's guide to the office measurement of cholesterol.
Burke JJ; Fischer PM
JAMA; 1988 Jun; 259(23):3444-8. PubMed ID: 3373682
[TBL] [Abstract][Full Text] [Related]
17. Accuracy of three dry-chemistry methods for lipid profiling and risk factor classification.
Rubin DA; McMurray RG; Harrell JS; Carlson BW; Bangdiwala S
Int J Sport Nutr Exerc Metab; 2003 Sep; 13(3):358-68. PubMed ID: 14669935
[TBL] [Abstract][Full Text] [Related]
18. Addressing unanswered questions about population cholesterol screenings: the Model Systems for Blood Cholesterol Screening Program.
Havas S; Greenland P; Wones R; Schucker B
Am J Prev Med; 1989; 5(6):337-46. PubMed ID: 2597429
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of two compact analyzers used for lipid analysis.
McKenney JM; Fary DF; Miller G; Proctor JD; Chinchili VM
J Fam Pract; 1993 May; 36(5):526-33. PubMed ID: 8482937
[TBL] [Abstract][Full Text] [Related]
20. [Population screening on a population level in Leipzig within the scope of the Bavarian cholesterol project].
Richter V; Rassoul F; Reuter W; Otto J; Richter WO; Schwandt P; Rotzsch W
Z Gesamte Inn Med; 1992 Aug; 47(8):359-61. PubMed ID: 1413928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
